Key facts
- This page summarizes Markus Warmuth's Form 3 filing for Monte Rosa Therapeutics, Inc. (GLUE).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Jun 2021, 20:38.
Markus Warmuth - 23 Jun 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)
- Reporting relationship
- President & Chief Executive Officer Exhibit 24 - Power of Attorney, Director
- Issuer ticker
- GLUE
- Reported as of
- 23 Jun 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 23 Jun 2021, 20:38:19 UTC
- Prior SEC filing
- 25 Jun 2021
- Next SEC filing
- 02 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ajim Tamboli, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Markus Warmuth filed Form 3 for Monte Rosa Therapeutics, Inc. (GLUE) on 23 Jun 2021.
Change
- Previous filing in this sequence was filed on 25 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GLUE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 416,538
- Date
- 23 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GLUE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 786,756
- Exercise price
- $2.19
- Footnotes
- F2
GLUE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 23 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 538,517
- Exercise price
- $6.14
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This amount consists of shares of restricted stock subject to vesting. As of the date hereof, 182,236 shares have vested and 234,302 shares remain unvested.
Footnote F2
25% of this option shall vest and become exercisable on December 4, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Footnote F3
25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
SEC remarks
President & Chief Executive Officer Exhibit 24 - Power of Attorney